2017年1月1日
Cancer Therapy Due to Apoptosis: Galectin-9.
International journal of molecular sciences
- 巻
- 18
- 号
- 1
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.3390/ijms18010074
- 出版者・発行元
- MDPI
Dysregulation of apoptosis is a major hallmark in cancer biology that might equip tumors with a higher malignant potential and chemoresistance. The anti-cancer activities of lectin, defined as a carbohydrate-binding protein that is not an enzyme or antibody, have been investigated for over a century. Recently, galectin-9, which has two distinct carbohydrate recognition domains connected by a linker peptide, was noted to induce apoptosis in thymocytes and immune cells. The apoptosis of these cells contributes to the development and regulation of acquired immunity. Furthermore, human recombinant galectin-9, hG9NC (null), which lacks an entire region of the linker peptide, was designed to resist proteolysis. The hG9NC (null) has demonstrated anti-cancer activities, including inducing apoptosis in hematological, dermatological and gastrointestinal malignancies. In this review, the molecular characteristics, history and apoptosis-inducing potential of galectin-9 are described.
- リンク情報
-
- DOI
- https://doi.org/10.3390/ijms18010074
- PubMed
- https://www.ncbi.nlm.nih.gov/pubmed/28045432
- PubMed Central
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297709
- Web of Science
- https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000393030600074&DestApp=WOS_CPL
- ID情報
-
- DOI : 10.3390/ijms18010074
- ISSN : 1422-0067
- PubMed ID : 28045432
- PubMed Central 記事ID : PMC5297709
- Web of Science ID : WOS:000393030600074